Copied to clipboard!

WES and RNA sequencing of mesothelioma patients from CONFIRM clinical trial

CONFIRM is a placebo controlled, double-blind randomised phase III clinical trial designed to investigate the efficacy of the anti-PD1 inhibitor nivolumab in patients with relapsed mesothelioma. This study applied the whole exome sequencing and transcriptomic sequencing to uncover determinants of efficacy in patients exhibiting the most extreme response outcomes.

Type: Cancer Genomics
Archiver: European Genome-phenome Archive (EGA)

1 Publication

Publications	Citations
Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial. Fennell DA, Hill K, Zhang M, Poile C, Ewings S, Baitei EY, Dzialo J, Nusrat N, Rogel J, Faulkner D, Ottensmeier C, Califano R, Hanna GG, Danson S, Steele N, Nye M, Johnson L, Mallard K, Lord J, Middleton C, Szlosarek P, Chan S, Darlison L, Wells-Jordan P, Richards C, Harber J, Bzura A, Spicer J, Pritchard C, Kamata T, Hahne JC, Jama M, Hollox EJ, Lester JF, Luo JL, Zhou Z, Yang H, Zhou H, Klampatsa A, Griffiths GO. Nat Commun 16: 2025 6688	2

Publications

Citations

Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial.
Fennell DA, Hill K, Zhang M, Poile C, Ewings S, Baitei EY, Dzialo J, Nusrat N, Rogel J, Faulkner D, Ottensmeier C, Califano R, Hanna GG, Danson S, Steele N, Nye M, Johnson L, Mallard K, Lord J, Middleton C, Szlosarek P, Chan S, Darlison L, Wells-Jordan P, Richards C, Harber J, Bzura A, Spicer J, Pritchard C, Kamata T, Hahne JC, Jama M, Hollox EJ, Lester JF, Luo JL, Zhou Z, Yang H, Zhou H, Klampatsa A, Griffiths GO. Nat Commun 16: 2025 6688